A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia: an experience learned from a Jehovah's Witness

BMJ Case Rep. 2015 Sep 30:2015:bcr2015211785. doi: 10.1136/bcr-2015-211785.

Abstract

It is well known that hydroxyurea can cause pancytopaenia secondary to bone marrow suppression, which is reversible with short-term discontinuation of the therapy. However, it is important to note that bone marrow suppressive effects caused by hydroxyurea could be easily potentiated in patients with sickle cell anaemia complicated by chronic kidney disease (CKD). We present a case of a Jehovah's Witness with sickle cell anaemia, who developed severe bone marrow suppression due to the combined effects of hydroxyurea and CKD, resulting in a prolonged recovery period after discontinuation of hydroxyurea.

Publication types

  • Case Reports

MeSH terms

  • Anemia, Sickle Cell / drug therapy*
  • Anemia, Sickle Cell / therapy
  • Blood Transfusion
  • Bone Marrow
  • Bone Marrow Diseases / etiology*
  • Enzyme Inhibitors / adverse effects
  • Humans
  • Hydroxyurea / adverse effects*
  • Hydroxyurea / therapeutic use
  • Jehovah's Witnesses*
  • Male
  • Middle Aged
  • Religion and Medicine*
  • Renal Insufficiency, Chronic / complications*

Substances

  • Enzyme Inhibitors
  • Hydroxyurea